Records containing: Influenza

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

• CLINICAL_TRIALS study record update · 2017-06-08
  Active-control Study to Evaluate the Safety, Tolerance and Immunogenicity of Fluviral™ S/F Influenza Vaccine in Healthy Adults Aged 18-64 Years of Age
• CLINICAL_TRIALS study record update · 2017-05-30
  An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age
• CLINICAL_TRIALS study record update · 2017-05-19
  Phase 4, School-based, Open-labeled Research Trial for Control of Epidemic Influenza Through a School-based Influenza Vaccination Program in Central Texas.
• CLINICAL_TRIALS study record update · 2017-05-12
  Randomized Phase 1 Double-Blinded Placebo Controlled Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Seasonal Influenza A Vaccine and dsRNA Adjuvant Administered Orally to Healthy Volunteers
• CLINICAL_TRIALS study record update · 2017-05-12
  Protective Mechanisms Against a Pandemic Respiratory Virus: B- Cell, T-cell, and General Immune Response to Seasonal Influenza Vaccine. Year 1, 2009
• Organize your saved records without ads with Plus.
• CLINICAL_TRIALS study record update · 2017-05-11
  Protective Mechanisms Against a Pandemic Respiratory Virus: B-Cell, T-cell, and General Immune Response to Seasonal Influenza Vaccine. Year 3, 2011
• CLINICAL_TRIALS study record update · 2017-05-11
  Vaccination and Infection: Indicators of Immunological Health and Responsiveness. Project 1: Plasmablast Trafficking and Antibody Response in Influenza Vaccination;
• CLINICAL_TRIALS study record update · 2017-05-10
  Tissue-specific Responses to Influenza Immunization and Their Relation to Blood Biomarkers. U19-HIPC Vaccination and Infection: Indicators of Immunological Health and Responsiveness
• CLINICAL_TRIALS study record update · 2017-05-10
  Observer-blind Monocentric Study in Adults Aged Between 18-60 Years to Evaluate Reactogenicity and Immunogenicity of 1 and 2 Administrations of Pandemic Monovalent Influenza Vaccines Administered at Different Antigen Doses and Adjuvanted or Not
• CLINICAL_TRIALS study record update · 2017-05-10
  Immunogenicity and Safety Study of GSK Biologicals' Cell Culture Derived Pandemic Influenza Vaccines GSK2590066A and GSK2592984A Administered to Healthy Adults 18 - 49 Years Old
• CLINICAL_TRIALS study record update · 2017-05-08
  A Partially-blind Multi-centric Study in Adults Aged Between 18-60 Years Designed to Evaluate the Reactogenicity and Immunogenicity of 1 and 2 Doses of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) Administered at Different Doses and Adjuvanted or Not
• CLINICAL_TRIALS study record update · 2017-05-08
  An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK2789869A and GSK2789868A Administered in Adults 21 to 64 Years of Age
• CLINICAL_TRIALS study record update · 2017-05-08
  A Phase I/II, Open, Controlled Study in Order to Evaluate the Reactogenicity and the Immunogenicity of GlaxoSmithKline Biologicals Influenza Candidate Adjuvanted Vaccine in an Elderly Population Aged Over 65 Years Previously Vaccinated in 2004 With the Same Candidate Vaccine
• CLINICAL_TRIALS study record update · 2017-05-08
  Immunogenicity and Safety Study of GSK Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral®, Thimerosal-free (FluLaval® TF), in Adults 18 to 60 Years of Age.
• CLINICAL_TRIALS study record update · 2017-05-04
  Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (GSK2340272A) in Children Aged 3 to 9 Years
• CLINICAL_TRIALS study record update · 2017-05-02
  Adolescent Vaccination in the Medical Home
• CLINICAL_TRIALS study record update · 2017-05-02
  Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine (GSK2340274A) in Japanese Children Aged 6 Months to 17 Years
• CLINICAL_TRIALS study record update · 2017-04-28
  Incidence of H1N1v Influenza-like Illness and Risk Factors for Serious Influenza Forms in HIV Infected Patients
• CLINICAL_TRIALS study record update · 2017-04-28
  A Controlled Trial to Assess the Immunogenicity and Efficacy of Three Vaccine Dosing Strategies in HIV Infected Adults
• CLINICAL_TRIALS study record update · 2017-04-24
  A Phase II/III, Observer-blind, Multi-Country, Multi-Centre, Randomized Study to Demonstrate the Superiority in Terms of Immunogenicity of Adjuvanted Influenza Vaccine Administered in Adults Aged 50 Years and Older Compared to Fluarix™
• CLINICAL_TRIALS study record update · 2017-04-24
  Evaluation of Anti-Hemagglutinin Antibodies as a Correlate of Protection in an H1N1 Influenza Healthy Human Challenge Model
• CLINICAL_TRIALS study record update · 2017-04-21
  A Phase III, Observer-Blind, Randomized Multicenter Study to Evaluate the Safety of Trivalent Subunit Influenza Vaccines, Produced Either in Mammalian Cell Culture (TIVc) or in Embryonated Eggs (TIV), in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related Complications
• CLINICAL_TRIALS study record update · 2017-04-20
  A Phase II, Open-Label, Uncontrolled, Single Center Study to Evaluate Safety and Immunogenicity of a Commercially Available Surface Antigen, Inactivated Influenza Vaccine, Formulation 2006-2007, When Administered to Non-Elderly Adult and Elderly Subjects
• CLINICAL_TRIALS study record update · 2017-04-14
  The Role of Immunizing Pregnant Women In Protecting Young Infants Against Influenza
• CLINICAL_TRIALS study record update · 2017-04-07
  A Phase 1 Clinical Study With Influenza Antiviral DAS181-F04: Double-Blind, Randomized, Placebo-Controlled, Multi Dose Study in Healthy Adults